Biobanking study to understand cancer and immune response
Official title: Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Run by Institut Curie · NCT03017573 · Data updated 2026-11-12
This study is collecting tumor and blood samples from cancer patients to see how their tumors and immune responses change during treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1050 (estimated) |
| Sponsor | Institut Curie Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 6 sites (Bordeaux and 5 other locations) |
| Status | Recruiting |
| Started | January 6, 2017 |
| Main results expected | August 6, 2029 |
| Study ends | January 6, 2032 |
| Registry record updated | February 3, 2026 |
| Trial ID | NCT03017573 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with newly diagnosed, treatment-naïve ovarian, triple-negative breast, head and neck, cervical, or sarcoma cancers who are eligible for surgery or neoadjuvant chemotherapy.
✕Probably not a fit
Patients under 18 years old or those with conditions that may hinder compliance with the study protocol will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study collects tumor and blood samples from patients with various types of cancer, including ovarian, triple-negative breast, head and neck, cervical, and sarcoma. It aims to identify new molecular and immunological biomarkers that correlate with the clinical and biological characteristics of these tumors. Patients will undergo standard treatments while providing samples at multiple time points, such as before and after surgery and during chemotherapy. The goal is to better understand the link between tumor alterations, the tumor microenvironment, and the immune response.
Why it matters
Potential benefit: If successful, this study could lead to the discovery of new biomarkers that improve cancer treatment and patient outcomes.
How similar studies have gone: Other studies focusing on molecular and immunological biomarkers in cancer have shown promise, indicating that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Tumor types : 1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy 2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy 3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery 4. Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancer patients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2). 5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma or (2) uterine sarcoma eligible for surgery or systemic treatment 2. Male or female patients ≥ 18 years of age 3. Signed informed consent Exclusion Criteria: 1. Male or female patients ≤18 years old 2. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 3. Individually deprived of liberty or placed under the authority of a tutor 4. Patients not affiliated to the Social Security System
Where it's running
-
Institut Bergonie
Bordeaux, France Recruiting -
Centre Oscar Lambret
Lille, France Recruiting -
Centre Leon Berard
Lyon, France Recruiting -
Institut Curie
Paris, France Recruiting -
Institut Curie Hopital Rene Huguenin
Saint-Cloud, France Recruiting -
Institut de Cancérologie de Lorraine - Nancy
Vandœuvre-lès-Nancy, France Not yet recruiting
Study contacts
- Principal investigator: Edith BORCOMAN, Prof. — Institut Curie
- Study coordinator: Anne-Sophie PLISSONNIER
- Email: drci.promotion@curie.fr
- Phone: 01 47 11 23 78
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
-
Virtual exercise program to preserve function and prevent disability during chemotherapy
This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.
-
Validation of a blood test for early cancer detection and monitoring
This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
Riluzole to prevent thinking and memory problems during chemotherapy
This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.
-
Navigation program for young cancer survivors
This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.